Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00603668 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00603668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2008
Completion date
February 28, 2013
Enrollment
19 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic lymphoma